Background. It is postulated that some aspects of methotrexate toxicity may be related to its action as an anti-folate. Folic acid (FA) is often given as an adjunct to methotrexate therapy, but there is no conclusive proof that it decreases the toxicity of methotrexate and there is a theoretical risk that it may decrease the efficacy of methotrexate.
Rheumatologists are increasingly using methotrexate to methotrexate was as effective as i.m. gold in reducing radiological progression in RA [3] . As with any drug, treat rheumatoid arthritis (RA) and are starting it earlier there are concerns about short-and long-term toxicity, in the course of the disease [1] . In a meta-analysis of 66 and it is postulated that some aspects of methotrexate randomized controlled trials involving 3957 patients toxicity may be related to its action as an anti-folate with RA treated with methotrexate for between agent [4] . Folic acid is commonly, though not univer-3 months and 2 yr, methotrexate was found to be as sally, given as an adjunct to methotrexate therapy but effective as intramuscular gold, sulphasalazine and peniit has not yet been proven conclusively that it decreases cillamine in reducing joint pain, tenderness and erythromethotrexate toxicity, and there is a theoretical risk that cyte sedimentation rate ( ESR) and increasing grip it may decrease the efficacy of methotrexate [5] . strength [2] . A meta-analysis of 17 trials found that
The exact mechanism of action of methotrexate in RA remains uncertain. Methotrexate is an anti-folate agent. The polyglutamated derivatives of methotrexate dihydrofolate reductase and 5-aminoimidazole-4-carboxamide ribonucliotide transformalase. Inhibitory have investigated whether it is necessary to continue folic acid supplementation in the long term in patients effects on cytokines, particularly interleukin-1, and on arachidonic acid metabolism, as well as effects on proestablished on methotrexate. In summary, there is no consensus amongst rheumatoteolytic enzymes, have been reported. Some might be related to the anti-folate properties of methotrexate.
logists about the necessity for folic acid supplementation for patients receiving low-dose methotrexate [4] . The Overall, the drug appears to act in RA as an antiinflammatory agent with subtle immunomodulating purpose of our study was to expand on the work done previously and had the following objectives: (1) to look properties [4] .
A number of researchers have investigated the relaat the effect of stopping folic acid supplementation in UK patients who are established on methotrexate tionship between folate status and toxicity/efficacy in RA patients receiving methotrexate. Morgan et al. [6] <20 mg weekly and folic acid 5 mg daily; (2) to report all toxicity, including absolute changes in haematological used an assay of the folate-dependent enzymatic synthesis of serine from formate and glycine (the C1 index) and liver enzyme indices; and (3) to report any changes in the efficacy of methotrexate. to compare folate status between RA patients taking methotrexate and those not taking methotrexate. They reported that the activity of the enzyme system in Materials and methods lymphocytes was significantly lower in the methotrexateStudy design treated group. None of the patients in their study experienced toxicity with methotrexate treatment. They
The study was a prospective, randomized, double-blind concluded that some depletion of folate coenzyme levels placebo-controlled study. Patients who were established in lymphocytes may be necessary for a clinical response on methotrexate <20 mg weekly and folic acid 5 mg in RA, whereas excessive depletion causes toxic sidedaily were asked to stop their folic acid and were effects. Weinblatt and Fraser [7] investigated a retrorandomized to one of two groups: placebo or folic acid spective series of patients treated with methotrexate and 5 mg daily. Patients were randomized using a balanced found that all patients with haematological toxicity were allocation method [11] in order to achieve equal distribufolate-deficient. They therefore concluded that haematotion of the following characteristics: duration of methological toxicity is related to folate depletion. It has also trexate use; age; gender; duration of RA; concurrent been suggested that other side-effects of methotrexate prednisolone use; concurrent use of non-steroidal antiadministration, such as gastrointestinal intolerance, inflammatory drugs (NSAIDs); and mean joint erosion mimic folate deficiency and may be related to folic acid score. Patients received visually identical capsules condeficiency [8] .
taining inert placebo or folic acid 5 mg. The capsules Given this evidence of the effect of methotrexate on were manufactured especially for the study by Nova folate metabolism and the possible link with side-effects, Laboratories (Leicester, UK ). Neither the investigators, the question arises as to whether supplements decrease the patients, nor the treating rheumatologists were aware the frequency of side-effects. A recent meta-analysis of of the placebo/folic acid capsule assignments until the randomized controlled trials [9] concerned with the study was complete. Patients were withdrawn from the addition of folic acid or folinic acid to methotrexate study at the discretion of the treating rheumatologist. identified only two studies (67 patients treated with folic
Patients and methods acid) that looked at folic acid; both studies were reported by the same group of US investigators [5, 8] . Both
The subjects were patients with definite or classic RA [12] attending the Staffordshire Rheumatology Centre studies looked at patients starting methotrexate and folic acid concurrently. The first study followed patients (SRC ), UK. The laboratory and clinical data regarding disease-modifying anti-rheumatic drug (DMARD) for only 24 weeks, but the second study included a longer period of follow-up (48 weeks). Both studies therapy for all patients with inflammatory arthritis have been recorded on a computer drug-monitoring database reported the number of patients experiencing neutropenia and elevations of liver transaminases, but unfortuat the SRC since 1987 [13] . The names of all patients (200) currently taking methotrexate were obtained from nately the absolute levels were not included in the papers so these could not be included in the meta-analysis. The the database. Patients were excluded if they did not have RA; if they were aged under 18 yr; if they were on studies conducted by Morgan et al. [5, 8] were both conducted in the USA, where baseline dietary intake of unstable doses of methotrexate; if they were taking methotrexate in combination with another type of folic acid may differ from that in the UK. The numbers of patients studied were small (32 and 79) and the DMARD; if they were not on folic acid 5 mg daily; if the total white blood cell ( WBC ) count was <3 × 109; studies may have had insufficient power to detect differences in the efficacy of methotrexate in the different if the neutrophil count was <2 × 109; or if the aspartate transaminase (AST ) or alanine transaminase (ALT ) treatment groups. The studies have been criticized for using a mean toxicity score, which may have resulted in concentration was outside the normal range. All suitable patients were approached about participating in the some side-effects influencing the overall result more than others. The studies have also been criticized for not study. Seventy-five patients were recruited for the study and gave informed consent to participation. The study including 'hard' outcome measures, such as the progression of joint erosions on X-ray [10] . No studies to date was approved by the North Staffordshire Health 
Results

Outcome measures
Seventy-five patients (age range 19-78 yr) were enrolled Patients were evaluated for treatment toxicity and effiin the trial: 38 patients were allocated to treatment with cacy before entry and then at intervals of 3 months for folic acid and 37 to placebo treatment. The demographic 1 yr. The assessments were carried out by two experiand selected clinical features of the two groups were enced metrologists (SC, JF ). The primary outcome similar ( Table 1) . studied was the cessation of methotrexate treatment due to inefficacy or toxicity.
Primary outcome
The number of patients discontinuing the study is seen Secondary outcomes in Table 2 . Overall, 25 (33%) patients concluded the Minor toxicity. This was measured using a checklist of study early: 8 patients (21%) in the group remaining on 24 symptoms.
folic acid and 17 (46%) in the placebo group. Thus, 30 Treatment efficacy. This was evaluated with the following of 38 patients in the folic acid group vs 20 of 37 in the measures: (1) a visual analogue scale ( VAS ) for pain placebo group remained on methotrexate treatment (0-100 mm); (2) eight activities of daily living assessed (P = 0.02) for the 12-month follow-up period. Three and averaged at baseline and at 12 months using the patients in the placebo group discontinued the study modified Health Assessment Questionnaire and scored because of nausea and vomiting or mouth ulcers vs one on a scale of 1 (no difficulty) to 4 (unable to perform) patient in the folic acid group. No patients were withdrawn from the study with hepatic measured using a VAS (0-100 mm); (7) the duration of abnormalities but two patients in the placebo group morning stiffness expressed in minutes; (8) mean grip were withdrawn because neutrophils were <2 × 109/l strength (three measurements for both hands expressed (in accordance with current national guidelines) and in mm Hg; (9) the proximal interphalangeal joint score three patients were withdrawn because of chest symp- [16 ] ; and (11) the number of corticosteroid joint toms. Summary details of all five patients are given in injections. Table 3 . Unfortunately, we did not include the neutroLaboratory assessments. The following estimations phil count as one of the variables included in our were made at baseline and thereafter at intervals of balanced allocation method of randomization. This 3 months: full blood count (FBC ), WBC, absolute resulted in the placebo group having a lower mean WBC neutrophil count, c-glutamyl transferase (GGT ), AST, and neutrophil count at baseline ( Table 1) . However, ALT and ESR.
all patients who started the study had parameters within Radiographic assessment. Hand and feet radiographs the normal range and two patients in the placebo group were taken before starting the study and at completion. did develop neutrophil counts outside the normal range. Radiographs were given Larsen scores [17] by a single There was one report of chest problems in the folic acid blinded radiologist (JS ).
group and two reports in the placebo group. It is difficult Miscellaneous. Data were also collected on current to define methotrexate-related chest disease clinically, medications and doses, and Hospital Anxiety and so patients and clinicians are advised to suspect the Depression Scores were recorded [18] . diagnosis in patients who become short of breath. It is unlikely that the chest symptoms in these patients were Statistical analysis related solely to their methotrexate therapy. These cases All calculations were undertaken with NCSS-PASS 1992 illustrate that it is often difficult to establish whether (Dr J. L. Hintze, Kaysville, Utah, USA). stopping a drug is related to toxicity or other factors.
Sample size and analysis
In a recent study, 40% of patients established on longSecondary outcomes term DMARDs reported possible adverse events over a
Minor toxicity follow-up period of 1 yr [19] . If taking folic acid reduces the number of patients experiencing adverse events to Table 4 shows the incidence of minor side-effects during the study. The two groups reported different incidences 10%, then a sample size of 32 in each group with a twosided significance level of 5% will have a power of 80% of paraesthesiae and ankle oedema at baseline. The placebo group reported slightly higher incidences of to detect such a difference. dizziness at 3 months (P < 0.05) and nausea at 9 months
After withdrawing from the study she was re-established on her usual (P < 0.001).
medication of methotrexate 10 mg weekly and folic acid 5 mg daily. 
Treatment efficacy
*P < 0.05; **P < 0.01; ***P < 0.001. Table 5 shows that the placebo group had a lower total 3. At 9 months there was an increased incidence of nausea in the placebo group (45 vs 7%, P = 0.001). but these were unlikely to be of clinical significance.
lation of methotrexate poyglutamates in liver biopsies Discussion from patients with RA who also had folate deficiency. The main finding of this study was that there were fewer However, although no correlation could be shown breaks from methotrexate treatment in patients who between folate levels, methotrexate polyglutamate accucontinued with folic acid 5 mg daily than in those who mulation and transaminase elevations, this may be a discontinued folic acid. Two patients in the placebo possible mechanism for the liver toxicity of methotrexate. group demonstrated a fall in neutrophils during the Serum folate levels were not included in this study study. The data showed occasional statistical differences because the Lactobacillus casei assay that is available in methotrexate treatment efficacy in the two groups locally is inhibited by small concentrations of methotrexbut, in general, the measures of treatment efficacy were ate. Folate levels can be measured by a radioimmune the same in the two groups. The other results worthy of assay or, as in the studies by Morgan et al. [5, 6, 8] , comment were the fact that three patients in the placebo folate status can be indirectly evaluated by an assay of group discontinued the study because of nausea and the activity of an enzyme system which synthesizes serine vomiting or mouth ulcers vs one in the folic acid group. from glycine and formate and requires folate coenzymes. The placebo group also reported more nausea than the This activity is called the C1 index [5, 6 ] . Previous folic acid group at 9 months (7 vs 45%, P = 0.001).
investigators have commented on the relationship Despite the fact that low-dose methotrexate has between folate levels and methotrexate toxicity. Morgan become standard therapy for RA, its mechanisms of et al. [5] found that low-normal initial folate levels in action with respect to efficacy, as well as its side-effects, their placebo group were correlated with a high probabilare still obscure. The rapid improvement and exacerbaity of eventual methotrexate toxicity [5] . A greater tion after respectively introducing and discontinuing increase in mean corpuscular volume (MCV ) was also methotrexate suggests the possibility of an antinoted in the placebo group. A further study from the inflammatory effect as well as an immunomodulating same investigators also reported that low blood folate effect [20] [26 ] proposed that the ability of hydroxychloroquine to Side-effects are quite common during treatment with increase the size and number of lysosomes in hepatocytes methotrexate. The severity varies, but most side-effects stabilizes the membrane and thereby exerts its protective are mild, reversible, and can be treated conservatively.
effect. Reduced bioavailability of methotrexate may also However in approximately 30% of patients with RA, account for these effects [20] . Indeed, it can also be toxicity leads to discontinuation of methotrexate therapy argued that folic acid reduces the side-effects of methowithin 1 yr. However, although the risk of side-effects trexate solely by reducing its bioavailability (methotrexmay be slightly higher in the first 6 months, the risk of ate blocks dihydrofolate reductase, resulting in depletion all sorts of adverse effects is permanent, implying a need of intracellular reduced folates, and competes with dihyfor long-term monitoring [20] .
drofolate to inhibit the distal steps in the synthesis of At least part of the side-effect profile of methotrexate nucleotides [25] ). If this were the case, then it would be seems to be directly related to its folate antagonism and expected that folate supplements would diminish the its cytostatic effects, especially in tissues with a high cell efficacy of methotrexate. One reason for the design of turnover (bone marrow and gastrointestinal tract), our study (stable patients on methotrexate plus folic which have a high requirement for purines, thymidine acid randomized to placebo or folic acid ) was to better and methionine [20] . Most of the reported side-effects observe changes in methotrexate efficacy between the in our study were related to bone marrow and the two groups. If additional folic acid was reducing the biological actions of methotrexate, then an improvement gastrointestinal tract. Kremer et al. [22] showed accumu- 
